Free Newsletter
SPOTLIGHT: Acambis contract offers long-term funding
The announcement that Acambis has won a $425 million, 10-year contract to supply the U.S. government with its smallpox vaccine, along with a new share placement, will provide the company with enough cash to fund operations for the medium term. To win the contract, Acambis had to agree to produce the vaccine in the U.S. Report
Comments
Post new comment
Paid Research Reports
- Cloud Computing Adoption In The APAC Life Sciences Industry
- Pharmaceutical Licensing Overview
- Stakeholder Opinions: Vaccines in emerging markets (Latin America) - Opportunities in Brazil, Mexico and Argentina
- Pharmaceutical Key Trends 2010
- Commercial Insight: Top 20 Oncology Therapy Brands in Australia
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities


SHARE
WITH: